© Copyright 2004-2020 PharmaInformatic Boomgaarden. All rights reserved.         Site map           Contact         Terms of Use         Imprint        

PharmaInformatic provides
ADME Knowledge Bases
 and Expert Systems
for drug discovery
and toxicological
risk assessment.

Berlin, January 2020:
The project results of our current research project
(Animal-free toxicity testing)
were presented at the

The company was founded in 2004 and is based in Emden, Germany.

  Get In Contact

    LinkedIn   Twitter

Welcome to PharmaInformatic !

Global scientific collaboration against coronavirus 2019-nCoV outbreak is needed:

New potent drug candidates against coronavirus must achieve sufficient effective concentration in blood, high enough to erase the virus in the systemic circulation of humans.

The effective concentration in human blood is reduced by low drug uptake (oral bioavailability) and high plasma protein binding. PharmaInformatic has developed unique expert systems to calculate these key drug properties for any novel compound (for example 3CLPro or PLpro protease inhibitors).

Ralph Baric of the University of North Carolina explained in Science dated 27.1.2020:  ...proteins in the human body bind 99% of these protease inhibitors, leaving little of them to fight viruses. “They’re effective against HIV because it’s so damn sensitive to the drug,” Baric says. Coronaviruses, by comparison, are insensitive. “You cannot achieve a free level of drug in a human that will allow it to work."


New technology to evaluate Plasma Protein Binding of compounds by Artificial Intelligence:

PharmaInformatic has developed the largest and comprehensive annotated knowledge base on Plasma Protein Binding of compounds worldwide. It now contains more than 17.000 data records taken from more than 2.400 scientific publications. The technology improves toxicity assessment of compounds and discovery of new drugs. A current validation study showed a high quality of prediction (more).


IMPACT-F:  Prediction of oral bioavailability in humans (drug-uptake)

The expert system IMPACT-F evaluates oral bioavailability of future drugs in humans. The technology is used to optimise lead candidates. Predictions were shown to be much more precise than animal trials: they were as accurate as the common deviation between individual humans taking part in the same clinical trial. (research results).


Oral bioavailability is one of the most important properties of a drug. If a new drug candidate has low or no oral bioavailability, further drug development is stopped. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market. Efficacy issues have been identified as the main reason why clinical trials fail. Pharmaceutical companies use IMPACT-F to evaluate drug-uptake in humans prior to clinical trials.